NB
78 programs · 75 companies
Programs
78
Companies
75
Trials
76
MOAs
46
GLP-1agAuroraAiTYK2iPI3KiCDK4/6iWRNiKRASG12CiFXIaiVEGFiCFTRmod
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | NDA/BLA | CD19 | ||
| Voxarasimod | Phase 1/2 | CD19 | ||
| MRK-2473 | Phase 1/2 | Nectin-4 | ||
| Voxacilimab | Phase 1/2 | GLP-1R | ||
| VRT-5441 | Phase 3 | GLP-1R | ||
| Pemitapinarof | Approved | KRASG12C | ||
| Niralucimab | Phase 1 | ALK | ||
| Pexanesiran | Phase 1 | BCMA | ||
| Gozeosocimab | Phase 2 | BCMA | ||
| Talazasiran | NDA/BLA | MET | ||
| Elracapivasertib | Phase 3 | PRMT5 | ||
| Zoriosocimab | Approved | C5 | ||
| Tixafotisoran | Phase 3 | FLT3 | ||
| Kemanesiran | Approved | JAK1 | ||
| SLD-1824 | Phase 2 | EZH2 | ||
| 450-8514 | Phase 3 | RET | ||
| 451-4848 | Preclinical | TIM-3 | ||
| Sovafotisoran | NDA/BLA | FGFR | ||
| Fixatapinarof | Preclinical | PLK4 | ||
| Zoribrutinib | Preclinical | B7-H3 | ||
| Zenozasiran | Preclinical | BET | ||
| Bemabrutinib | Phase 1 | GPRC5D | ||
| BHC-6524 | Approved | Cl18.2 | ||
| SAM-IIT-450 | Phase 2/3 | PARP | ||
| Zanulemzoparlimab | Phase 1 | JAK2 | ||
| MIR-7357 | Preclinical | USP1 | ||
| Suraosocimab | Phase 1 | PSMA | ||
| ISO-9327 | Phase 1 | KRASG12C | ||
| IPS-8044 | Preclinical | FXIa | ||
| Pexasertib | Preclinical | CD38 | ||
| Fixafutibatinib | Preclinical | SMN2 | ||
| Miricilimab | Phase 2 | C5 | ||
| FOR-9610 | Phase 2 | TYK2 | ||
| Olpasertib | Phase 3 | DLL3 | ||
| Voxafotisoran | Phase 2 | MDM2 | ||
| CLO-7126 | Preclinical | PARP | ||
| Datorasimod | NDA/BLA | FGFR | ||
| Tezecilimab | Approved | VEGF | ||
| CAN-3547 | NDA/BLA | FcRn | ||
| NOR-1166 | Phase 1 | WRN | ||
| EVO-4804 | Approved | IL-17A | ||
| OCU-3469 | Phase 1 | LAG-3 | ||
| Cevifutibatinib | Phase 1 | BCL-2 | ||
| MIM-1147 | Phase 2 | TYK2 | ||
| MIM-9797 | Phase 2/3 | BCL-2 | ||
| Riluratamab | Preclinical | KRASG12C | ||
| GH-9188 | Phase 1 | CDK4/6 | ||
| Tirazanubrutinib | NDA/BLA | MET | ||
| Semacagene | Phase 1/2 | SGLT2 | ||
| 418-6056 | Phase 1/2 | BCL-2 | ||
| 415-4068 | NDA/BLA | DLL3 | ||
| Ivorasimod | Phase 3 | HER2 | ||
| 003-4903 | Phase 3 | BCMA | ||
| 199-2212 | Phase 2/3 | C5 | ||
| 532-4982 | Phase 3 | CDK4/6 | ||
| AUR-9187 | Phase 2 | PD-L1 | ||
| SVA-6795 | NDA/BLA | CDK4/6 | ||
| Talatinib | Phase 2 | Aβ | ||
| VAL-4454 | Preclinical | Aβ | ||
| GEN-516 | Phase 2/3 | PLK4 | ||
| Elrarapivir | Phase 2 | Nectin-4 | ||
| BER-6094 | Phase 3 | CDK2 | ||
| NEO-620 | Phase 2/3 | IL-13 | ||
| MYG-309 | NDA/BLA | EGFR | ||
| Zorirapivir | NDA/BLA | IL-17A | ||
| Tiranesiran | Preclinical | MALT1 | ||
| BIO-IIT-157 | Phase 1 | VEGF | ||
| LAB-7111 | NDA/BLA | PRMT5 | ||
| NAT-IIT-296 | Preclinical | GIP-R | ||
| AII-IIT-336 | Preclinical | Aβ | ||
| Adagraratamab | NDA/BLA | CFTR | ||
| Polacapivasertib | Approved | JAK1 | ||
| Teraosocimab | Approved | C5 | ||
| Liramavacamten | Phase 1 | CD38 | ||
| KRK-5622 | Phase 2 | Tau | ||
| Bemafotisoran | Preclinical | PRMT5 | ||
| CDX-409 | Approved | CD123 | ||
| Sovazanubrutinib | Phase 2/3 | CDK2 |
Trials (76)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT05781362 | PFE-8662 | NDA/BLA | Not yet recr... |
| NCT08402918 | Voxarasimod | Phase 1/2 | Recruiting |
| NCT07009582 | Voxarasimod | Phase 1/2 | Recruiting |
| NCT05848076 | Voxacilimab | Phase 1/2 | Recruiting |
| NCT08696939 | VRT-5441 | Phase 3 | Active |
| NCT03098118 | VRT-5441 | Phase 3 | Not yet recr... |
| NCT07402260 | VRT-5441 | Phase 3 | Not yet recr... |
| NCT07909843 | VRT-5441 | Phase 3 | Terminated |
| NCT08751608 | Pemitapinarof | Approved | Not yet recr... |
| NCT08385295 | Pemitapinarof | Approved | Recruiting |
| NCT04456812 | Niralucimab | Phase 1 | Active |
| NCT05557723 | Niralucimab | Phase 1 | Active |
| NCT05879648 | Pexanesiran | Phase 1 | Completed |
| NCT04669754 | Pexanesiran | Phase 1 | Recruiting |
| NCT03848008 | Zoriosocimab | Approved | Terminated |
| NCT05589801 | Tixafotisoran | Phase 3 | Recruiting |
| NCT08231177 | Tixafotisoran | Phase 3 | Completed |
| NCT06456444 | Tixafotisoran | Phase 3 | Recruiting |
| NCT04401988 | SLD-1824 | Phase 2 | Not yet recr... |
| NCT07393032 | SLD-1824 | Phase 2 | Recruiting |